Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes - PubMed (original) (raw)
Randomized Controlled Trial
. 2005 Dec 22;353(25):2643-53.
doi: 10.1056/NEJMoa052187.
Affiliations
- PMID: 16371630
- PMCID: PMC2637991
- DOI: 10.1056/NEJMoa052187
Randomized Controlled Trial
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
David M Nathan et al. N Engl J Med. 2005.
Abstract
Background: Intensive diabetes therapy aimed at achieving near normoglycemia reduces the risk of microvascular and neurologic complications of type 1 diabetes. We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease.
Methods: The DCCT randomly assigned 1441 patients with type 1 diabetes to intensive or conventional therapy, treating them for a mean of 6.5 years between 1983 and 1993. Ninety-three percent were subsequently followed until February 1, 2005, during the observational Epidemiology of Diabetes Interventions and Complications study. Cardiovascular disease (defined as nonfatal myocardial infarction, stroke, death from cardiovascular disease, confirmed angina, or the need for coronary-artery revascularization) was assessed with standardized measures and classified by an independent committee.
Results: During the mean 17 years of follow-up, 46 cardiovascular disease events occurred in 31 patients who had received intensive treatment in the DCCT, as compared with 98 events in 52 patients who had received conventional treatment. Intensive treatment reduced the risk of any cardiovascular disease event by 42 percent (95 percent confidence interval, 9 to 63 percent; P=0.02) and the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57 percent (95 percent confidence interval, 12 to 79 percent; P=0.02). The decrease in glycosylated hemoglobin values during the DCCT was significantly associated with most of the positive effects of intensive treatment on the risk of cardiovascular disease. Microalbuminuria and albuminuria were associated with a significant increase in the risk of cardiovascular disease, but differences between treatment groups remained significant (P< or =0.05) after adjusting for these factors.
Conclusions: Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes.
Copyright 2005 Massachusetts Medical Society.
Figures
Figure 1. Cumulative Incidence of the First of Any of the Predefined Cardiovascular Disease Outcomes (Panel A) and of the First Occurrence of Nonfatal Myocardial Infarction, Stroke, or Death from Cardiovascular Disease (Panel B)
As compared with conventional treatment, intensive treatment reduced the risk of any predefined cardiovascular disease outcome by 42 percent (95 percent confidence interval, 9 to 63 percent; P = 0.02) (Panel A) and reduced the risk of the first occurrence of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57 percent (95 percent confidence interval, 12 to 79 percent; P = 0.02) (Panel B).
Comment in
- Glycemic control and cardiovascular disease--should we reassess clinical goals?
Cefalu WT. Cefalu WT. N Engl J Med. 2005 Dec 22;353(25):2707-9. doi: 10.1056/NEJMe058282. N Engl J Med. 2005. PMID: 16371637 No abstract available. - Intensive diabetes treatment and cardiovascular disease.
Weissman AJ. Weissman AJ. N Engl J Med. 2006 Apr 20;354(16):1751-2; author reply 1751-2. doi: 10.1056/NEJMc060105. N Engl J Med. 2006. PMID: 16625015 No abstract available. - Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes.
Gerstein HC. Gerstein HC. ACP J Club. 2006 May-Jun;144(3):63. ACP J Club. 2006. PMID: 16646607 No abstract available.
Similar articles
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up.
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Diabetes Care. 2016 May;39(5):686-93. doi: 10.2337/dc15-1990. Epub 2016 Feb 9. Diabetes Care. 2016. PMID: 26861924 Free PMC article. Clinical Trial. - Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).
White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. White NH, et al. J Pediatr. 2001 Dec;139(6):804-12. doi: 10.1067/mpd.2001.118887. J Pediatr. 2001. PMID: 11743505 - Long-term effects of intensive glucose lowering on cardiovascular outcomes.
ACCORD Study Group; Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. ACCORD Study Group, et al. N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524. N Engl J Med. 2011. PMID: 21366473 Free PMC article. Clinical Trial. - Intensive glycemic control and cardiovascular disease: an update.
Brown A, Reynolds LR, Bruemmer D. Brown A, et al. Nat Rev Cardiol. 2010 Jul;7(7):369-75. doi: 10.1038/nrcardio.2010.35. Epub 2010 Apr 20. Nat Rev Cardiol. 2010. PMID: 20404853 Review.
Cited by
- Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes.
Grutzmacher C, Park S, Zhao Y, Morrison ME, Sheibani N, Sorenson CM. Grutzmacher C, et al. Am J Physiol Renal Physiol. 2013 Jan 1;304(1):F19-30. doi: 10.1152/ajprenal.00036.2012. Epub 2012 Oct 17. Am J Physiol Renal Physiol. 2013. PMID: 23077100 Free PMC article. - The economic costs of diabetes: is it time for a new treatment paradigm?
Herman WH. Herman WH. Diabetes Care. 2013 Apr;36(4):775-6. doi: 10.2337/dc13-0270. Diabetes Care. 2013. PMID: 23520368 Free PMC article. No abstract available. - Pharmacological properties of protocatechuic Acid and its potential roles as complementary medicine.
Semaming Y, Pannengpetch P, Chattipakorn SC, Chattipakorn N. Semaming Y, et al. Evid Based Complement Alternat Med. 2015;2015:593902. doi: 10.1155/2015/593902. Epub 2015 Feb 9. Evid Based Complement Alternat Med. 2015. PMID: 25737736 Free PMC article. Review. - The interplay of autoimmunity and insulin resistance in type 1 diabetes.
Nokoff NJ, Rewers M, Cree Green M. Nokoff NJ, et al. Discov Med. 2012 Feb;13(69):115-22. Discov Med. 2012. PMID: 22369970 Free PMC article. Review. - Improving Care in Older Patients with Diabetes: A Focus on Glycemic Control.
Lee EA, Gibbs NE, Martin J, Ziel F, Polzin JK, Palmer-Toy D. Lee EA, et al. Perm J. 2016 Summer;20(3):15-080. doi: 10.7812/TPP/15-080. Epub 2016 Jun 29. Perm J. 2016. PMID: 27352408 Free PMC article.
References
- Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676–85. - PubMed
- Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864–71. - PubMed
- Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. - PubMed
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9. [Erratum, N Engl J Med 2000; 342:1376] - PMC - PubMed
- Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750–5. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical